Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 395
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 274
MAFLD: a multisystem disease
Rosaria Maria Pipitone, Carlo Ciccioli, G. Infantino, et al.
Therapeutic Advances in Endocrinology and Metabolism (2023) Vol. 14
Open Access | Times Cited: 104
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 87
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?
Mariana M. Ramírez-Mejía, Carlos Jiménez-Gutiérrez, Mohammed Eslam, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 168-178
Closed Access | Times Cited: 54
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 19
MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?
Christopher D. Byrne, Giovanni Targher
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 16
Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease
Ludovico Abenavoli, Tiziana Larussa, Alessandro Corea, et al.
Nutrients (2021) Vol. 13, Iss. 2, pp. 494-494
Open Access | Times Cited: 102
A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know
Mark Muthiah, Ng Cheng Han, Arun J. Sanyal
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 3-14
Open Access | Times Cited: 84
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne, Giovanni Targher
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 28-43
Open Access | Times Cited: 79
Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
Stergios A. Pοlyzos, Stergios Kechagias, Emmanuel Tsochatzis
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 8, pp. 1013-1025
Open Access | Times Cited: 79
Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Veera Houttu, Susanne Csader, Max Nieuwdorp, et al.
Frontiers in Nutrition (2021) Vol. 8
Open Access | Times Cited: 72
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy (2021) Vol. 38, Iss. 5, pp. 2130-2158
Open Access | Times Cited: 67
Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches
Paola Dongiovanni, Erika Paolini, Alberto Corsini, et al.
European Journal of Clinical Investigation (2021) Vol. 51, Iss. 7
Open Access | Times Cited: 56
A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet
Mohammed Abdullah Alshawsh, Abdulsamad Alsalahi, Salah Abdalrazak Alshehade, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 858-858
Open Access | Times Cited: 56
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
Stuart McPherson, Matthew J. Armstrong, Jeremy Cobbold, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 8, pp. 755-769
Open Access | Times Cited: 52
Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality
Cheng Han Ng, Zhen Yu Wong, Nicholas Chew, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 46
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Olufunto O. Badmus, Terry D. Hinds, David E. Stec
Current Hypertension Reports (2023) Vol. 25, Iss. 8, pp. 151-162
Open Access | Times Cited: 40
Research Advances of Engineered Exosomes as Drug Delivery Carrier
Lianghui Huang, Enguang Wu, Jiawei Liao, et al.
ACS Omega (2023) Vol. 8, Iss. 46, pp. 43374-43387
Open Access | Times Cited: 35
The Role of Probiotics and Their Metabolites in the Treatment of Depression
Monika Elżbieta Jach, Anna Serefko, Aleksandra Szopa, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3213-3213
Open Access | Times Cited: 31
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials
Armin Ebrahimzadeh, Shokouh Mohseni, Mohammad Safargar, et al.
Complementary Therapies in Medicine (2024) Vol. 80, pp. 103025-103025
Open Access | Times Cited: 15
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1859-1859
Open Access | Times Cited: 13
The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis
Qiong Lv, Hua-Shan Zhao
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 8
Hepatokines and Their Role in Cardiohepatic Interactions in Heart Failure
Wael A Shouman, Sarah Najmeddine, Lilas Sinno, et al.
European Journal of Pharmacology (2025), pp. 177356-177356
Closed Access | Times Cited: 1
Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in nonalcoholic fatty liver disease
Lu Xu, Jingyang Zhou, Jinhui Che, et al.
AJP Gastrointestinal and Liver Physiology (2021) Vol. 320, Iss. 6, pp. G1034-G1044
Closed Access | Times Cited: 54
Page 1 - Next Page

Scroll to top